As artificial intelligence continues to shape the future of healthcare, the need for standardized approaches to digital biomarkers has never been more urgent. In 2025, regulatory bodies are stepping up their frameworks to ensure that algorithms used for physiological monitoring—such as heart rate, respiration, HRV, and stress—are safe, reproducible, and clinically validated.
The FDA’s recent draft guidance on AI-enabled Software as a Medical Device (SaMD) emphasizes traceability of data sources, structured model updates, and the need for continuous post-market surveillance. Similarly, the EU’s Medical Device Regulation (MDR) is enforcing stricter conformity assessments for devices that leverage biometric-derived data.
At the core of these emerging standards is the demand for transparency: clinical-grade algorithms must demonstrate explainability, generalizability, and fairness. ISO/IEC is currently finalizing a standard that outlines quality benchmarks for AI systems interpreting physiological signals, including rPPG and passive wearables. Compliance will likely become essential for reimbursement, risk classification, and international market access.
For digital health innovators, aligning early with these evolving frameworks isn’t just a compliance exercise—it’s a product and investment strategy. Standardized AI means more trust, faster approvals, and sustainable scalability.